Streetbeat News

Revenues

PSMT

PriceSmart Inc (NASDAQ:PSMT) shares rose approximately 9% after reporting Q1 FY24 results that surpassed expectations. Revenue increased by 10.6% year-over-year to $1.17 billion, beating the consensus of $1.16 billion. Net merchandise sales grew by 10.7% year-over-year to $1.14 billion, with foreign currency exchange rate fluctuations contributing positively. Comparable net merchandise sales for the 50 warehouse clubs open for over 13 ½ months rose by 8.0%. Adjusted EBITDA was $77.8 million, up from $75.2 million a year ago, and adjusted EPS of $1.24 exceeded the consensus of $1.09. The company had $275 million in cash and equivalents and increased its warehouse clubs count to 53 from 50 the previous year. PSMT shares are trading higher at $80.10 in premarket.

Portfolio Pulse from Lekha Gupta

January 10, 2024 | 12:40 pm

DKNG

DraftKings is set to launch its highly-rated online sportsbook in Vermont on January 11, expanding its market presence and potentially increasing its user base and revenue streams.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 12:33 pm

RPID

Rapid Micro Biosystems has reported preliminary Q4 FY23 revenue in the range of $6.2M-$6.4M, reflecting a 45% increase year-over-year, which is in line with the consensus estimate of $6.25M.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 12:24 pm

RPID

Rapid Micro Biosystems announced preliminary FY23 revenue between $22.4M-$22.6M, reflecting a 30% increase year-over-year and aligning with the consensus estimate of $22.41M.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 12:23 pm

AMRN

Amarin Corporation has announced preliminary total revenues for FY23 in the range of $304M-$306M, surpassing the consensus estimate of $294.18M.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 12:13 pm

AMRN

Amarin Corporation has announced preliminary Q4 FY23 total revenues of $72M-$74M, surpassing the consensus estimate of $62.03M.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 12:12 pm

RNLX

Renalytix has announced that a real-world evidence study published after 12 months of follow-up shows that its KidneyIntelX in vitro prognostic testing is associated with clinical actions that significantly slow the progression of chronic kidney disease (CKD).

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 12:08 pm

TGTX

TG Therapeutics projects Q1 BRIUMVI U.S. net product revenue to be between $41M and $46M. For FY24, the company anticipates revenue to range from $220M to $260M.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 12:07 pm

ELIQ

Electriq Power Holdings, Inc. (ELIQ) plans to launch 10 new Sustainable Community Networks in Los Angeles County, California, offering zero-upfront cost solar + battery storage systems to homeowners, particularly benefiting low-to-moderate income residents. The systems aim to reduce electricity costs by up to 20%, provide price stability, and offer backup power. The PoweredUp Network program is expected to be available to roughly 400,000 residents by the end of Q1'2024.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 12:07 pm

TGTX

TG Therapeutics announced that its BRIUMVI product generated $40M in US net revenue for Q4 and $89M for the full year of FY23. This financial update is crucial for investors as it reflects the company's revenue-generating capability from this product.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 12:06 pm